Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

Pearlstein, Teri; Bachmann, Gloria; Zacur, Howard A.; Yonkers, Kimberly A.

doi:10.1016/j.contraception.2005.08.021

Cited by 231 publications

(166 citation statements)

References 21 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Although it was proven that oral contraceptive pills had no effect on mood, new regimens with 24 active pills and 4 placebo days, combined with a progestin drospirenone have been approved by US Food and Drug Administration for the treatment of PMDD. 20 This may be an option for whom desires hormonal contraception with severe premenstrual symptoms.…”

mentioning

confidence: 99%

Prevalence of Premenstrual Symptoms Among College Students

Ekin¹,

Ekin²,

Savan³

2013

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

mentioning

confidence: 99%

Prevalence of Premenstrual Symptoms Among College Students

Ekin¹,

Ekin²,

Savan³

2013

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

“…Ancak tedavi devamını etkileyen yan etkiler de saptanmıştır. En sık izlenen yan etkiler baş ağrısı, intermenstruel kanama, meme hassasiyeti ve bulantıdır [14,15]. Günümüzde drospirenon içeren COC'ler için en önemli tartışma ilacın alınmadığı 7 günlük dönemde semptomların yeteri kadar rahatlamayacağıdır.…”

Section: İstatistiksel Analizunclassified

Ethinyl Estradiol-Drospirenon Versus Vitex Agnus-Castus Extract in Efficacy of the Treatment of Premenstrual Syndrome

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

“…Five trials had suffi cient information in the registry to be included in this review. One trial did not contain suffi cient information in the registry, but was linked to a publication [10] A total of six trials met the pre-defi ned patient group, intervention, comparisons, outcomes (PICO) criteria and had suffi cient information for analyses. One trial was performed using drospirenone (DR) and ethinyl-estradiol (EE) as the active treatment.…”

Section: Searchmentioning

confidence: 99%

Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials

Yum

Ryu

Park

et al. 2012

Korean J Obstet Gynecol

View full text Add to dashboard Cite

Up to 80% of women experience physical and emotional changes that are related to their menstrual cycle. Among the nearly 150 reported cyclically recurrent emotional and somatic symptoms, the most common include irritability, fatigue, depression or mood swings, breast tenderness, bloating, and food cravings [1][2][3]. Approximately 3%-8% of reproductive-age women experience mood, behavioral and/or physical symptoms during the fi nal week of their menstrual cycle that are severe enough to meet the criteria for premenstrual dysphoric disorder (PMDD) [4][5][6]. PMDD is thought to result from the complex interaction among ovarian steroid production, endogenous opioid peptides, central neurotransmitters, prostaglandins, and peripheral autonomic and endocrine systems [7][8][9]. Of the wide range of medications available for this treatment approach, the most commonly used agents are oral contraceptives and antidepressants. As a clinician faced with patients who complain of premenstrual symptoms, it is difficult to predict which symptoms will benefit from treatment with which drug. In some cases, it is puzzling on the part of both patients and physicians whether premenstrual distress requires medical treatment at all. Often, patients read about alternative remedies advertised in beauty magazines, newspapers, television ads, the internet, and seek advice from friends and family. There is overwhelming amount of information on which underwear to wear, which foods to eat and avoid, special herbs, drinks, even lucky charms. In the midst of all the available remedies, one wonders what role medications can have in the competition. This paper aims to summarize and help readers understand the evidence, and ultimately help physicians make practical decisions about pharmacotherapy for PMDD. The primary objective of this review is to search for signals regarding the following questions: Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient's global function. Patients and physicians alike are often uncertain whether prescription medication for PMDD is suffi ciently effective. The primary objective of this analysis is signal detection in effi cacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confi rmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective.

show abstract

Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

Cited by 231 publications

References 21 publications

Prevalence of Premenstrual Symptoms Among College Students

Prevalence of Premenstrual Symptoms Among College Students

Ethinyl Estradiol-Drospirenon Versus Vitex Agnus-Castus Extract in Efficacy of the Treatment of Premenstrual Syndrome

Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials

Contact Info

Product

Resources

About